Clinical Trial Update: Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission [Phase 2]

View source ↗

Summary

Phase 2 trial of MLN9708 as maintenance therapy in AML and high-risk MDS patients in remission was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• MLN9708 (ixazomib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2018-10-03